Radiation Therapy Definitions and Reporting Guidelines for Thymic Malignancies  by Gomez, Daniel et al.
ITMIG DEFINITIONS AND POLICIES
Radiation Therapy Definitions and
Reporting Guidelines for Thymic Malignancies
Daniel Gomez, MD,* Ritsuko Komaki,* James Yu, MD,† Hitoshi Ikushima, MD, PhD,‡
and Andrea Bezjak, MSc, FRCPC, MD§
Key Words: Surgery, Lung function, Preoperative evaluations.
(J Thorac Oncol. 2011;6: S1743–S1748)
The role of radiation therapy in the treatment of thymicmalignancies is still being established, and many details
that have never been clearly defined are currently being
critically examined. Such an assessment has been hampered
by significant inconsistency in how radiotherapy (RT) is
delivered, how the RT field is defined, which patients are
selected for treatment, and how outcomes are reported. An
opportunity to change this has arisen through the develop-
ment of the International Thymic Malignancy Interest Group
(ITMIG), which is an organized collaboration of individuals
interested in this field. The prerequisite to progress, however,
is to establish definitions and consistent policies, so that
results can be understood and compared. This is the topic
addressed in this article.
METHODS
A workgroup was assembled to review literature rele-
vant to the issues and formulate preliminary recommenda-
tions (Daniel Gomez, Ritsuko Komaki, James Yu, Hitoshi
Ikushima, and Andrea Bezjak). These were refined by an
extended workgroup (Charles Thomas, Lynn Wilson, Greg-
ory Videtic. James Metz, Harun Badakhshi, Clifton Fuller,
Francoise Mornex, Conrad Falkson, David Ball, and Ken
Rosenzweig) and discussed further in a broad ITMIG multi-
disciplinary workshop meeting, which was supported by the
International Association for the Study of Lung Cancer. A
draft of this article, containing the proposed policies and
standard operating procedures, was then disseminated to all
ITMIG members for further discussion. The final version of
this article was then written, taking all the input into consid-
eration, and was ultimately approved by the ITMIG members
for use in ITMIG collaborative initiatives.
BASIC DEFINITIONS
Clinical Setting and Treatment Intent
The mainstay of treatment of thymomas and other
thymic malignancies is surgery. RT is predominantly used
after surgery, to reduce the risk of mediastinal relapse. How-
ever, it can be used in other clinical scenarios as well, such as
part of definitive treatment for patients that are not medically
operable or for tumors that are not resectable after a regimen
of preoperative chemotherapy. As most patients have disease
confined to the thorax, RT fields often encompass one or
more thoracic structures (mediastinum, pleura, and occasion-
ally pericardium) and typically with the aim of local control
and tumor eradication. However, in the setting of recurrent
disease, the doses and intent may vary, e.g., lower doses
mainly aimed at symptom improvement, rather than disease
eradication, may be employed. Thus, a clear statement of the
clinical context (setting), aim, and area treated with radiation
is needed, so that reports can be more meaningfully compared
to determine the outcomes after radiotherapy and advance the
treatment of thymic malignancies. The following definitions
are proposed, as summarized in Table 1.
Clinical context (setting)
Y Preoperative, i.e., before surgery—RT or chemotherapy
alone may be administered or a regimen of concurrent or
sequential chemotherapy and RT may be used.
Y Postoperative, i.e., after surgery—treating oncologists
and authors of publications should indicate whether
postoperative RT is being given in setting of complete
resection (R0), microscopic residual disease (R1), or
gross residual disease (R2), as RT doses used may vary.
If both postoperative radiation and postoperative che-
motherapy are administered, that should be indicated as
well, as it may affect both toxicity and outcomes. Post-
operative RT may be given to part or all the mediasti-
num, pericardium, hemithorax, or to portions of the
pleura if resection of pleural metastases was performed.
Y Definitive RT (alone or combined with chemotherapy)—if
there are no plans for surgery, RT alone or chemoradia-
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tion is being used as primary treatment of the thymic
malignancy.
Y RT for recurrent disease—area of recurrence needs to be
specified, as well as the type of RT (external beam,
endobronchial brachytherapy, and intraoperative).
Aims
Y Curative—with the intent to definitively treat the dis-
ease, e.g., for long-term disease control.
Y Palliative—with the aim of symptom improvement
and/or reduction in tumor size but not eradication of
tumor being irradiated.
Area treated
Y Gross tumor with margin (primary tumor or lymph
nodes).
Y Tumor bed with margin (as delineated by preoperative
and postoperative imaging and surgical findings, includ-
ing surgical clips).
Y Elective sites beyond initially involved area (mediasti-
num and lymph nodes).
Y Sites of pleural metastases (either in postoperative set-
ting, after resection, or in a curative or palliative setting,
e.g., pleural effusion or pleural implants).
Y Entire hemithorax (right or left).
Outcome Assessments of Particular Relevance
to RT
The article “Standard Outcome Measures for Thymic
Malignancies” provides specific definitions of appropriate
survival measures and which patients should be included in
the reporting of specific events, as well as definition of
recurrences (time, and whether local, regional, or distant) and
a discussion on how to measure and assess response to
treatment (chemotherapy and radiation).1 Briefly, local recur-
rence is defined as disease appearing in the bed of the thymus,
regional recurrence is intrathoracic tumor that is not “imme-
diately contiguous with the thymus gland or previous thymic
neoplasm,” and distant recurrence is disease outside of this
region, to include intrapulmonary nodules. Future studies
should be specific and report outcomes according to these
definitions. Of specific interest with respect to RT is whether
a local or regional recurrence occurring after postoperative
RT is within, at the margin of, or outside the RT field (defined
by the relationship to the beam edge). This specification is of
particular interest in the modern era, as treatment planning
has shifted from wide-field two-dimensional planning (cov-
ering large areas of mediastinum) to more conformal three-
dimensional (3D) planning with a reduction of the area
treated to tumor bed and/or anterior mediastinum—this shift
has the potential of increasing marginal and out of field
failures. Careful and detailed reporting of recurrences and
their relationship to the RT fields and pooling of the data are
required to ascertain that changes in RT techniques are not
adversely affecting the outcomes of patients with thymic
malignancies.
RADIATION TECHNIQUES
Patient Positioning and Simulation
Patients should be strictly immobilized, preferably in a
supine position with the neck slightly extended and with their
arms over their head, if possible. This position will allow for
multifield planning techniques using oblique coplanar and/or
noncoplanar beam angles. A computed tomography (CT)
simulation should be performed, with 3- to 5-mm slices.
Intravenous contrast may be considered to better differentiate
the target and normal structures. When available, a four-
dimensional (4D) CT scan should be performed, to assess for
internal motion during treatment planning.2 If no 4D CT scan
is available, the treating radiation oncologist can consider the
following to assess the magnitude of internal motion: (1) a
slow helical 4D CT scan that acquires images during the
entire breathing cycle and (2) CT images at full inspiratory
and expiratory phases, with the difference being estimated as
TABLE 1. Summary of Reporting Guidelines and Data
Fields for Thymic Malignancies Treated with Radiation
Therapy
Reporting Category Data Fields
Intent Palliative
Preoperative (downstaging or downsizing)
Curative
Sole modality
With concurrent or sequential chemotherapy
Postoperative
Postoperative R0 resection
Postoperative R1 resection
Postoperative R2 resection
Radiation field
(report all that
apply)
Gross tumor with margin
Tumor bed with margin
Elective sites beyond initially involved area (i.e.,
mediastinum and lymph nodes)
Sites of pleural metastases
Hemithorax
Radiation dose Date initiated and date completed
Radiation dose, initial volume (Gy)
Radiation fraction size, initial volume (Gy)
Boost given: yes/no
Boost timing: sequential/concurrent
Boost dose (Gy)
Boost fraction size (Gy)
Radiation technique 2D planning
3D conformal therapy
IMRT
Proton therapy
Other
Local recurrence
after radiation
In field
Marginal recurrence
Out-of-field
Radiation toxicity (use
Common Toxicity
Criteria for Adverse
Events v4.0, report
all that apply)
Grades 3–5: Esophagitis/cardiac/respiratory/other
Maximal toxicity grade (3–5)
Toxicity duration
Dose-limiting toxicity: yes/no
IMRT, intensity modulated radiation therapy.
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the magnitude of movement during breathing. A fusion of the
treatment planning CT scan with a fluorodeoxyglucose-pos-
itron emission tomography scan can serve as a useful adjunct
in the treatment planning process.3
The following target volumes should be reported:
Y Gross tumor volume (GTV), if present—gross disease.
Y Clinical target volume (CTV)—GTV plus microscopic
spread or area thought to be at risk for microscopic
spread. Historically, the CTV has covered the whole
mediastinum, to also include the preoperative extent of
disease. Nevertheless, with the availability of more pre-
cise imaging, including the widespread use of CT sim-
ulation, a more limited CTV is generally more appro-
priate, to encompass the postoperative region at risk as
indicated by preoperative imaging and intraoperative
findings, including the placement of surgical clips to
indicate regions at particular risk for persistent disease.
Treating physicians should specify if they are treating
the involved sites (gross tumor or tumor bed) with a
margin or elective sites beyond the initially involved
area, such as the lymph nodes or the mediastinum.
Y Internal target volume (ITV)—CTV plus internal mo-
tion.
Y Planning target volume (PTV)—ITV plus patient setup
error.
In the postoperative setting, target volumes should be
delineated using a combination of the patient’s preoperative
and postoperative imaging. The preoperative imaging should
be assessed to determine the initial extent of disease.
Target margins are dependent on the techniques used
during simulation and treatment planning, such as a 4D CT
simulation and daily kV imaging. If these modalities are not
available, then larger margins could be considered, depending
on the location of the tumor (with more inferior tumors
expected to move more) and the treating physician’s confi-
dence in daily setup. Acceptable margins are as follows:
Y GTV to CTV margin: 0.5 to 1.0 cm.
Y CTV to PTV margin, without 4D CT simulation (or
equivalent) and without daily kV imaging: 1.0 to 1.5 cm.
Y ITV to PTV margin, with 4D CT simulation (or equiv-
alent) but without daily kV imaging: 0.5 to 1.0 cm.
Y ITV to PTV margin, with 4D CT simulation and daily
kV imaging: 0.5 cm.
A joint ITMIG radiologist/radiation oncologist task
force is developing a consensus atlas for cancers of the
thymus, to include contour delineation recommendations.
Radiation Treatment Planning
Historically, RT for thymoma has been delivered with
two-dimensional techniques and simple field arrangements
such as opposed lateral fields. Nevertheless, given the ad-
vances in radiation technology in the past several years,
conformal techniques are highly recommended if available to
spare the surrounding mediastinal structures. These tech-
niques include 3D conformal radiation and intensity modu-
lated RT (IMRT).
“3D conformal radiation” is defined as the use of
multiple beams and the creation of a dose volume histogram
to evaluate the dose delivered to the tumor and normal
structures (specifically, doses to at least the following struc-
tures: esophagus, heart, lungs, and the spinal cord). “Intensity
modulated radiation therapy” (IMRT) is defined as treatment
through the arrangement of multiple beams, similar to 3D
conformal planning, with the addition of the capability to
alter the fluence of the radiation beam during treatment
delivery and that of inverse planning (the ability to specify
constraints to various structures before beam arrangement). If
IMRT is available, then this technique offers the advantage of
improved conformality over 3D conformal treatment. The
improvement in therapeutic ratio of IMRT over 3D conformal
therapy has been shown in several dosimetric studies in lung
cancer and in a recent clinical study assessing survival and
toxicity endpoints in 3D conformal RT versus IMRT in this
disease.4 Although there has never been a direct comparison
in the setting of thymoma, the advantages of conformality
could be expected to be extrapolated in this malignancy as
well, which is located in the mediastinum as well, near the
same critical structures. If IMRT is used, then the American
Society for Therapeutic Radiation Oncology guidelines (http://
www.astro.org/Research/ResearchHighlights/documents/IMRT.
pdf) can and should be used by the treating physician to optimize
treatment planning, as reinforced by the National Cancer Com-
prehensive Network guidelines for the treatment of thymic
malignancies (www.nccn.org). The radiation technique should
be described as outlined in Table 1, in the category radiation
technique.
Dosimetric Parameters for Thymoma
Table 2 outlines appropriate dosimetric parameters on
normal structures to be used in the setting of thymoma,
adapted from the most recent Quantitative Analysis of Nor-
mal Tissue Effects in the Clinic guidelines and applicable to
all sites of thoracic RT.5 The total elapsed days of treatment,
fraction size, energy, treatment field configuration, total dose,
and dose volume histogram parameters should be clearly
described.
POSTOPERATIVE RADIATION FOR THYMOMA
Postoperative RT After Completely Resected
Thymoma (R0)
Postoperative radiation is typically administered within
3 months after surgery. If initial postoperative imaging indi-
cates no residual disease and radiation is not initially recom-
mended but subsequently on later imaging the tumor recurs
and becomes grossly visible, then radiation given at this point
is for “recurrent” disease, the intent of radiation is no longer
“postoperative.” The treatment should be documented, both
clinically and for the purposes of publication, as “radiation
for recurrent disease.” We propose that the minimum post-
operative dose that can be counted as adjuvant RT for
thymoma after surgery is 40 Gy, in 1.8 to 2 Gy fractions, even
when no residual disease remains. The dose, regardless of
setting, should be reported as described in Table 1 in radia-
tion dose and include date initiated, date completed, total
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dose, fraction size, dose to initial field, and dose to boost
field. Doses for “hemithoracic” fields are a separate issue
distinct from the treatment of the surgical bed and are
discussed later. When the tumor has been completely re-
sected, minimum fields for postoperative radiation should
encompass the preoperative extent of disease, as indicated by
preoperative imaging and regions of risk identified intraop-
eratively. If no other areas are treated, this field should be
reported as “tumor bed with margin.” If elective sites are
treated, including the entire mediastinum or elective lymph
nodes, the field should be reported as “elective sites beyond
initially involved area” (as summarized in Table 1, radiation
field). If lymph nodes are biopsy proven to be grossly in-
volved with disease, nodal irradiation is no longer “elective.”
Note that any treatment of established disease only should be
defined as “involved field,” or as defined earlier, “gross tumor
with margin,” whether that field encompasses, for example,
the primary site and an involved node, or the primary site and
the site of a resected pleural implant.
Postoperative RT After Resection with a
Positive Margin (R1)
Timing of postoperative radiation after resection with a
positive margin is similar to that after a negative margin
resection (typically within 3 months of surgery), with the
exception that care must be taken to involve the surgeon and
pathologist in accurately defining the anatomy where micro-
scopic residual disease remains. Ideally, if the ITMIG rec-
ommendations for specimen handling at the time of resection
have been followed, such areas will have been clearly marked
with clips.6 Again, if immediate postoperative imaging shows
no gross residual disease and no radiation is initially recom-
mended but subsequent imaging that informs the decision for
radiation shows growth of grossly visible tumor, the intent of
radiation is for “recurrence” rather than “postoperative” ra-
diation. (It is important not to confuse hemostatic material
left in the operative field with an early recurrence).7 If
immediate postoperative imaging shows no gross residual
disease and radiation is initially recommended but preradio-
therapy imaging shows rapid regrowth of grossly visible
tumor, postoperative radiation should be defined as for “gross
residual” tumor after surgery and be recorded as R2 (the basic
definitions and standards are defined below). Doses below 40
Gy and above 64 Gy are not considered appropriate in the
postoperative setting but should be reported as described in
Table 1. With the higher dose range, normal tissue tolerance
must be respected. Again, doses for “hemithoracic” fields are
a separate issue, distinct from the treatment of the surgical
bed and are discussed below. When the tumor has been
completely resected, minimum radiation fields often encom-
pass presurgical involved areas, surgical clips, and areas
where the surgeon or pathologic review indicates positive
margins or the potential for residual microscopic disease.
Radiation fields should be reported as above, including the
categories “tumor bed with margin” or “elective sites beyond
initially involved area” (as summarized in radiation field in
Table 1). Nodal irradiation ceases to be elective if biopsy-
proven gross disease is present.
Postoperative RT After Surgery with Gross
Residual Disease (R2)
Timing of postoperative radiation after resection for
gross residual disease is the same as for a negative margin or
positive margin without gross residual disease: the time
interval should be documented. This time period is typically
within 3 months, though if a patient with gross residual
disease is then treated with a planned course of chemotherapy
followed by RT due to the presence of active disease, or
chemotherapy followed by chemoradiation, then the time
period between surgery and postoperative radiation may ex-
ceed 3 months and the radiation portion of the treatment is
best described as having “definitive” intent, as radiation for
progressive disease. Similarly, if radiation is not initially
planned after surgery and chemotherapy is given instead, but
radiation is subsequently recommended after chemotherapy
and fails to arrest tumor growth, this radiation should be
defined as radiation for “curative” intent, rather than “post-
operative radiation.” Radiation doses below 54 Gy are inad-
TABLE 2. Dosimetric Constraints to be Used and Reported
in the Treatment of Thymic Malignancies5
RT Alone
Chemotherapy
and RT
Chemotherapy
and RT Before
Surgery
Spinal corda Dmax 45 Gy Dmax 45 Gy Dmax 45 Gy
Lungb MLD 20 Gy MLD 20 Gy MLD 20 Gy
V20 40% V20 35% V20 30%
V10 45% V10 40%
V5 65% V5 55%
Heart V30 45% V30 45% V30 45%
Mean dose
26 Gy
Mean dose
26 Gy
Mean dose
26 Gy
Esophagus Dmax 80 Gy Dmax 80 Gy Dmax 80 Gy
V70 20% V70 20% V70 20%
V50 50% V50 40% V50 40%
Mean dose
34 Gy
Mean dose
34 Gy
Mean dose
34 Gy
Kidneyc 20 Gy 32% of
bilateral kidney
20 Gy 32% of
bilateral kidney
20 Gy 32% of
bilateral kidney
Liver V30 40% V30 40% V30 40%
Mean dose
30 Gy
Mean dose
30 Gy
Mean dose
30 Gy
a The size of the treated volume of the spinal cord should be considered, as the
chance of spinal cord damage increases with increasing treated volume. When PTV is
close (1 cm) to spinal cord such as vertebral invasion, the spinal cord may receive a
dose higher than recommended dose threshold to keep adequate dose to target volume
particularly GTV. Nevertheless, the spinal cord should not receive more than 60 Gy,
even in a very limited volume. A higher fraction size or a higher daily dose reduces
tolerance. If treatment is given in 3 Gy fractions, the constrained dose to the cord should
be approximately 40 Gy.
b V20  the effective lung volume (total lung volume  gross tumor volume)
receiving 20 Gy or more. For patients who undergo pneumonectomy before RT, we
recommend an MLD of 8 Gy, a V20 of 10%, and V5 60%. Note that in the setting
of postoperative treatment in which a gross total resection has been achieved, there is
no GTV, so the lung constraint will be representative of solely the total lung, not the
total lung minus the CTV.
c Consider a kidney scan if a large volume of one kidney will be treated with a
high dose.
RT, radiotherapy; MLD, mean lung dose; Dmax, maximal dose; PTV, planning
target volume; CTV, clinical target volume; GTV, gross tumor volume.
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equate for gross residual disease. Minimum radiation fields
encompass the gross disease as defined on cross-sectional
postoperative imaging and surgical clips. Radiation fields
should be reported as above, including the categories “gross
tumor with margin,” “elective sites beyond initially involved
area,” and/or “sites of pleural metastases.” Again, nodal
irradiation ceases to be elective should biopsy-proven gross
disease be present (see radiation dose and radiation field in
Table 1).
DEFINITIONS AND REPORTING GUIDELINES
FOR PREOPERATIVE RT
Preoperative chemotherapy, radiation, or combined
chemoradiation has been shown to be an effective treatment
strategy for locally advanced disease. After preoperative
therapy, patients should be assessed for disease response
approximately 3 to 6 weeks after the completion of treatment
with reimaging, to include a dedicated CT scan of the chest
with contrast. If at this time, patients are deemed to be
operative candidates, surgical resection should be performed
followed by an assessment for postoperative RT based on the
above guidelines. Indeed, if preoperative RT was delivered,
this dose should be taken into account in planning any future
radiation treatment, and a “composite plan” should be de-
vised for the purposes of normal tissue tolerance doses. This
composite plan will take into account for both the prior and
current radiation dose, though it should be noted that the dose
levels are not necessarily additive and/or often cannot be
specifically quantified. If at the time of reassessment after
preoperative treatment, surgery is still not a planned part of
treatment, further RT can be considered using the guidelines
for definitive RT described below. Nevertheless, a composite
treatment plan should again be attempted, and thus, it is likely
that if radiation is included in the preoperative therapy regi-
men, the dose of further radiation allowable will be limited.
In the preoperative setting, the treatment field should be
defined and reported using the guidelines above and using all
available imaging, to include the GTV with appropriate
margins for microscopic spread, internal motion, and patient
setup (CTV, ITV, and PTV). The technique of hemithoracic
RT is described below. A dedicated CT scan of the chest with
contrast is strongly recommended. Doses below 40 Gy and
above 64 Gy are not considered appropriate in the preoper-
ative setting. In the postoperative setting, the dosing guide-
lines above should be used and vary based on the extent of
resection achieved (R0 versus R1 versus R2), intraoperative
findings, and normal tissue constraints. The radiation dose
and radiation field should be reported as described in Table 1.
DEFINITIVE RT FOR THYMOMA
“Definitive radiation therapy” is defined as RT delivered
as the sole local modality for control of disease, although it is
often combined with chemotherapy for systemic treatment. It is
used in the setting of thymoma in patients who (1) are deemed
to be “medically inoperable” or (2) are not operative candidates
due to disease characteristics after preoperative therapy. “Med-
ically inoperable” is defined as being unable to tolerate the
appropriate surgical resection due to factors not related to the
malignancy, such as age, comorbidities, and performance status.
As noted earlier, “definitive radiation therapy” can also be
defined as treatment in which an R2 resection has previously
been performed, and thus, RT is being used as a primary local
modality for curative intent, with or without chemotherapy.
Treatment field guidelines should be delineated and reported as
outlined above and in Table 1, to cover the GTV with appro-
priate margins for microscopic spread, internal motion, and
patient setup variation, depending on the techniques available at
the institution. A dedicated CT scan of the chest with contrast
should be obtained. Doses below 54 Gy should not be consid-
ered definitive treatment.
THE ROLE OF HEMITHORACIC RT IN THE
MANAGEMENT OF THYMOMA
“Hemithoracic radiation therapy” is defined as radiation
encompassing the entire ipsilateral hemithorax electively in
addition to the PTV. The rationale for including a hemitho-
racic field is that thymomas have shown to have a potential
for pleural dissemination in prior studies,8 and it is thought
that low doses of radiation may sterilize this region. Appro-
priate treatment fields for hemithoracic RT have been defined
using an anterior/posterior radiation technique approximately
as follows: superior: thoracic inlet, or highest extent of
disease, inferior: insertion of diaphragm, lateral: 1 cm lateral
to the skin, and medial: contralateral vertebral body.8 Never-
theless, it should be noted that the target region in this
technique is the pleura and not necessarily the lung paren-
chyma, and although there are no studies examining using
conformal techniques such as IMRT to achieve lung sparing
in this setting, this will likely be a focus of future studies
assessing the safety and efficacy of minimizing normal tissue
dose by targeting solely the region at risk in the hemithorax.
Hemithoracic RT has been used in both stage II/III disease,9
and IVa disease.6,7 Typical doses of hemithoracic RT range
from 10 to 17 Gy in 7 to 16 fractions for low-stage disease
(stages II–III), with a boost to regions at high risk of up to 50
to 70 Gy (1.8–2.0 Gy fractions) and 45 to 54 Gy in stage IVa
disease with similar boost doses. The radiation treatment
volumes should be defined as outlined above (GTV, CTV,
ITV, and PTV). Regarding reporting guidelines (Table 1),
both the radiation dose to the hemithoracic region should be
reported, as well as the initial volume, with the dose and
fractionation specified, and subsequent radiation to the in-
volved tumor or regions at higher risk should be reported as
the boost volume, with the same specifications.
LOCAL RECURRENCES IN RT
Despite the many advantages of more conformal radi-
ation techniques, particularly IMRT, one potential disadvan-
tage is the possibility of a geographical miss. This type of
locoregional recurrence is defined either as progressive dis-
ease outside of the radiation field (designated as an “out-of-
field” recurrence) or in the region of high dose falloff (des-
ignated as a “marginal miss”). The concept of a marginal
miss with conformal techniques has been well elucidated in
other malignancies such as head and neck cancer,10–12 but
there is not a consensus in the literature as to a strict definition
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of a marginal miss. We propose that for reporting and
database purposes, a marginal miss is defined as local recur-
rence in which the geographic center of the recurrence lies in
the region between the prescription dose (100% prescrip-
tion dose) and the radiation field edge, defined as50% dose.
Out-of-field recurrences are defined as a local recurrence in
which the geographic center of the tumor is outside of the
field edge or 50% isodose line. Therefore, local recurrences
would be reported in one of three categories: in-field, mar-
ginal recurrence, and out-of-field. Although we acknowledge
that there will always be some degree of subjectivity in
defining a particular isodose line that is defined as a region of
“dose falloff,” and hence defining a recurrence in which
expanding the radiation field by a reasonable amount may
have prevented this event, these definitions will serve as a
guide to data collection and potential areas of improvement in
target delineation.
TOXICITY REPORTING GUIDELINES FOR
THYMIC TUMORS
All toxicities related to RT for thymic malignancies
should be reported according to the guidelines outlined in
Table 1. Relevant toxicities include esophagitis, pneumonitis,
dyspnea, dermatitis, and cardiac toxicities such as pericardi-
tis, arrhythmias, and coronary artery disease. Because of the
chronic nature of this disease and relatively high long-term
survival rates, both acute toxicity, defined by the Radiation
Therapy Oncology Group as within 3 months of the start of
RT, and chronic toxicity, defined as adverse events occurring
outside of this time period, should be recorded. Both the
Radiation Therapy Oncology Group and Common Toxicity
Criteria for Adverse Events criteria are acceptable, but the
treating physician should specify both the toxicity scoring
system and the version that is being cited.
CONCLUSION
Although many consensus guidelines pertaining to the
role of RT in thymic malignancies have been published, the
above recommendations serve to provide global reproducibil-
ity among outcome studies and to assist radiation oncologists
by providing a basis for medical record documentation,
retrospective review, and prospective assessment. By adher-
ing to the concepts provided in this article, the end goal is to
minimize ambiguity and inconsistency when defining treat-
ment paradigms and ultimately to build an ongoing database
that can be extracted and updated with limited effort and with
the confidence that the radiation terms described in these
guidelines do not vary based on factors such as geographic
region, practice setting, or reporting date. If this aim can
indeed be accomplished, it will be possible to publish future
studies both more rapidly and more accurately than has been
done in the past, thus accelerating progress pertaining to the
safety and efficacy of radiation in this rare but serious
malignancy.
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